Synthesis of defined oligohyaluronates-decorated liposomes and interaction with lung cancer cells

Cano, María Emilia; Lesur, David; Bincoletto, Valeria; Gazzano, Elena; Stella, Barbara; Riganti, Chiara; Berlier, Gloria; Kovensky, José

doi:10.1016/j.carbpol.2020.116798

Cited by 14 publications

(8 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Human pancreatic adenocarcinoma cells, Capan-1 and PANC-1, human breast cancer MCF-7 and MDA-MB-231 cells, and human non-small cell lung cancer Calu-3 and A549 cells were purchased from ATCC (Manassas, VA) and maintained in their respective medium (DMEM for Capan-1, PANC-1, and MCF-7, RPMI 16140 for MDA-MB-231 and Calu-3, and HAM's F12 for A549, all purchased from Invitrogen Life Technology, Milan, Italy) containing 1% v/v penicillin–streptomycin and 10% FBS (Merck, Milan, Italy). The surface amount of CD44, the receptor for HA, was evaluated by flow cytometry as previously described 81 using a Guava Millipore flow cytometer equipped with EasyCite software (Millipore, Bedford, MA).…”

Section: Methodsmentioning

confidence: 99%

Designing functionalized nanodiamonds with hyaluronic acid–phospholipid conjugates for enhanced cancer cell targeting and fluorescence imaging capabilities

Sturari,

Andreana,

Aprà

et al. 2024

Nanoscale

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Methodsmentioning

confidence: 99%

Designing functionalized nanodiamonds with hyaluronic acid–phospholipid conjugates for enhanced cancer cell targeting and fluorescence imaging capabilities

Sturari,

Andreana,

Aprà

et al. 2024

Nanoscale

Self Cite

View full text Add to dashboard Cite

show abstract

“…Concurrence studies have shown that the absorption has met the following ranking: HA-DP8 > HA-DP6 > HA-DP4 liposomes. Overall, the researchers suggested HA-DP oligosaccharides as the latest biocompatible and efficient methods of drug transmission to CD44-positive cells (Cano et al, 2020). One of the utmost essential advances in this area is the ability of liposomes to tackle the growing issue of multidrug resistance (MDR) attained by cancers, such significantly decreases the effectiveness of chemotherapy.…”

Section: Delivery Systemsmentioning

confidence: 99%

“…Cano et al prepared decorated liposomes with hyaluronic acid (HA) and oligosaccharides through the mark of polymerization (DP) 4, 6 and 8, attained through enzymatic depolymerization of HA. It was coalescing towards a PEG‐phospholipid component (Cano et al, 2020). In lung cancer cell lines, the cellular uptake of fluorescently labelled liposomes coated with HA‐DP4, HA‐DP6 and HA‐DP8 was significantly greater (12 to 14‐fold).…”

Section: Lipid‐based Drug Delivery Systemsmentioning

confidence: 99%

Perspectives on cutting‐edge nanoparticulate drug delivery technologies based on lipids and their applications

Maddiboyina¹,

Ramaiah²,

Nakkala³

et al. 2023

Chem Biol Drug Des

View full text Add to dashboard Cite

Numerous nanotech arenas in therapeutic biology have recently provided a scientific platform to manufacture a considerable swath of unique chemical entities focusing on drugs. Recently, nanoparticulate drug delivery systems have emerged to deliver a specific drug to a specified site. Among all other carriers, lipids possess features exclusive to nanostructured dosage forms. The bioavailability of orally administered drugs is typically negatively affected by their poor water solubility, resulting from the unique chemical moieties introduced. Because of their unique advantages, lipid nanoparticles must become increasingly predictable as a robust delivery mechanism. The enhanced biopharmaceutical properties and significance of lipid‐based targeting technologies such as liposomes, niosomes, solid lipid nanoparticles and micelles are highlighted in this review. Pharmaceutical implications of lipid nanocarriers for the transport and distribution of various therapeutic agents, such as biotechnological products and small pharmaceutical molecules, is a booming topic. Lipid nanoparticles as drug delivery systems have many appealing properties, including high biocompatibility, ease of preparation, tissue specificity, avoidance of reticuloendothelial systems, delayed drug release, scale‐up feasibility, nontoxicity and targeted delivery. The use of lipid nanoparticles to enhance the transport of biopharmaceuticals is currently considered state‐of‐the‐art. Similarly, we critically examine the upcoming guidelines that therapeutic scientists should handle.

show abstract

“…Moreover, uptake increased with increasing DP. HA-DP-decorated liposomes did not show cytotoxicity or inflammatory effects, suggesting that these conjugates may be used as biocompatible and effective tools for potential drug delivery to CD44+ cells [ 113 ]. The above-mentioned lipoplexes are lipid-based non-viral vectors that have been proposed as a means to transfer nucleic acids, such as plasmid DNA, siRNA and mRNA, to treat a wide range of disorders, from infectious and inherited diseases to cancer ( Figure 1 ).…”

Section: Ten Years Of Italian Research On Actively Targeted Nanocarriersmentioning

confidence: 99%

Developing Actively Targeted Nanoparticles to Fight Cancer: Focus on Italian Research

et al. 2021

Self Cite

View full text Add to dashboard Cite

Active targeting is a valuable and promising approach with which to enhance the therapeutic efficacy of nanodelivery systems, and the development of tumor-targeted nanoparticles has therefore attracted much research attention. In this field, the research carried out in Italian Pharmaceutical Technology academic groups has been focused on the development of actively targeted nanosystems using a multidisciplinary approach. To highlight these efforts, this review reports a thorough description of the last 10 years of Italian research results on the development of actively targeted nanoparticles to direct drugs towards different receptors that are overexpressed on cancer cells or in the tumor microenvironment. In particular, the review discusses polymeric nanocarriers, liposomes, lipoplexes, niosomes, solid lipid nanoparticles, squalene nanoassemblies and nanobubbles. For each nanocarrier, the main ligands, conjugation strategies and target receptors are described. The literature indicates that polymeric nanoparticles and liposomes stand out as key tools for improving specific drug delivery to the site of action. In addition, solid lipid nanoparticles, squalene nanoparticles and nanobubbles have also been successfully proposed. Taken together, these strategies all offer many platforms for the design of nanocarriers that are suitable for future clinical translation.

show abstract

Synthesis of defined oligohyaluronates-decorated liposomes and interaction with lung cancer cells

Cited by 14 publications

References 20 publications

Designing functionalized nanodiamonds with hyaluronic acid–phospholipid conjugates for enhanced cancer cell targeting and fluorescence imaging capabilities

Designing functionalized nanodiamonds with hyaluronic acid–phospholipid conjugates for enhanced cancer cell targeting and fluorescence imaging capabilities

Perspectives on cutting‐edge nanoparticulate drug delivery technologies based on lipids and their applications

Developing Actively Targeted Nanoparticles to Fight Cancer: Focus on Italian Research

Contact Info

Product

Resources

About